Camp4 Therapeutics Corp (CAMP) Form SCHEDULE 13D/A — Aug 19, 2026
Polaris-affiliated investors led by Amir Nashat filed Amendment No. 2 to their Schedule 13D on Camp4 Therapeutics, updating their reported beneficial ownership of common stock. The original 13D was filed October 22, 2024 and first amended September 11, 2025. The amendment exists solely to reflect dilution: Camp4's sales of additional common shares since the prior amendment cut the group's aggregate percentage ownership by more than 1%, with no purchases or sales by the reporting persons themselves.
Key figures
- Date Of Event
- 2026-08-13
- Brian Chee Shares
- 909090
- Amir Nashat Shares
- 3932251
- Brian Chee Percent
- 1.4%
- Amir Nashat Percent
- 6.3%
- Amy Schulman Shares
- 909090
- Amy Schulman Percent
- 1.4%
- Polaris Partners XShares
- 909090
- Polaris Partners XPercent
- 1.4%
- Polaris Partners Vii Shares
- 2825500
- Polaris Partners Vii Percent
- 4.5%
- Aggregate Ownership Decrease
- over 1% since Amendment No. 1 (filed 2025-09-11)
- Polaris Management Co Vii Shares
- 3023161
- Polaris Management Co Vii Percent
- 4.8%
- Polaris Entrepreneurs Fund Vii Shares
- 197661
- Polaris Entrepreneurs Fund Vii Percent
- 0.3%
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.